BriefMD

New research in your specialty, screened every morning.

Each morning BriefMD reads the new PubMed papers in your specialty and sends you the few worth your time, with each study's design, key numbers, a plain bottom line and a link to the source.

A recent brief, exactly as subscribers got itRead the whole brief

How it works

  1. Pick your specialty and topics

    Choose from 44 specialties, then narrow to the topics you follow. Add your own, like a drug, a procedure or a trial name.

  2. We screen PubMed overnight

    New papers are matched to your topics and ranked by study design and journal. Each summary is written from the abstract.

  3. Read it before rounds

    A few papers, each in under a minute. Get it daily, twice a week or weekly, and change that whenever your rotation does.

How papers are ranked

Every paper in your brief links back to PubMed, so you can always go to the source.

Read the full method

  1. Your topicsPapers outside the topics you follow stay out of your brief.
  2. Study designTrials, meta-analyses and large cohorts rank above case reports and lab work.
  3. JournalJournals you follow get their own section. Others are weighted by SCImago rank.
  4. Your feedbackEvery brief asks if it was useful, and the answers tune the ranking.

See this week's papers in your field

Real recent papers, summarized the way subscribers get them.

  1. systematic review, 1,005 patients

    Liver transplantation as a treatment option for neuroendocrine liver metastases: a systematic review

    Jaén-Torrejimeno I, López-Guerra D, Rojas-Holguín A, et al. Cir Cir. Jan 2026.

    Findings
    In a systematic review of 1005 patients (mean age 47.9 years), disease‑free survival after liver transplantation was reported as 25.3 months, ranging from 14 to 31 months.
    Bottom line
    The data suggest that liver transplantation can provide a disease‑free interval of about 25.3 months for patients with neuroendocrine liver metastases.

    PubMed, PMID 42913616

  2. prospective cohort, 285 patients

    Neutrophil-to-Lymphocyte Ratio Is Associated with Disease Progression in a Surveillance Cohort of Patients with Branch-Duct IPMN

    Hansen FJ, Ewald P, Sorncharoen L, et al. J Clin Med. Oct 2026.

    Findings
    During follow-up, 63 patients (22.1%) developed at least one WF, and patients with an NLR above the cohort median (>2.36) had approximately twofold higher odds of subsequent disease progression (OR, 2.02; 95% CI, 1.02-3.98).
    Bottom line
    Elevated NLR is linked to higher risk of BD‑IPMN progression, with an OR of 2.02 for patients above the median NLR.

    PubMed, PMID 42882217

  3. observational study, 1,000 patients

    Risk assessment of multi-focal side-branch IPMNs: Long-term follow-up of one thousand patients

    Wehrle CJ, Khan F, Nadeem MA, et al. Pancreatology. Oct 2026.

    Findings
    Among 1,000 patients, 370 (37%) had multifocal SB‑IPMNs; high‑risk pathology occurred in 4.3% overall (3.2% multifocal vs 4.8% solitary) and CR‑progression predicted malignancy (HR 31.3, 95% CI 16.3‑62.1).
    Bottom line
    Multiplicity does not raise malignant risk, but clinicians should monitor CR‑progression, which markedly predicts high‑risk pathology.

    PubMed, PMID 42897050

More new Surgical Oncology research

44 specialties, each with its own brief

See all specialties
Jonah Levine
Finding new studies isn't the hard part. Knowing which of the day's papers actually matter is. BriefMD is the email I wanted every morning: the new work in my field, the strongest evidence first.
Jonah Levine, founder. MD/MSc candidate, NYU Grossman. Why I built BriefMD

Start with tomorrow's brief.

Pick a specialty and topics after you subscribe. It takes about a minute.